Dicot AB

DICOT

SE0011178458

Pharmaceuticals

End-of-day quote NORDIC GROWTH MARKET Other stock markets 06:00:00 2024-05-21 pm EDT			5-day change	1st Jan Change
0.26 ^SEK	+1.76%		+1.56%	-18.24%

May. 06	Dicot AB Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 23	Dicot AB Announces Positive Safety and Improved Efficacy Results from Phase 1 Study	CI

Dicot AB Reports Earnings Results for the First Quarter Ended March 31, 2024

May 06, 2024 at 01:50 am EDT

Dicot AB (publ) reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported revenue was SEK 0.001 million compared to SEK 0.005 million a year ago. Net loss was SEK 13.64 million compared to SEK 9.94 million a year ago.

Latest news about Dicot AB

Dicot AB Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 06	CI
Dicot AB Announces Positive Safety and Improved Efficacy Results from Phase 1 Study	Apr. 23	CI
Dicot AB Announces Recruitment Completed in Dicot's Phase 1 Trial	Mar. 11	CI
Dicot AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 26	CI
Dicot AB Presents Positive Results from the First Part of its Phase 1 Clinical Study	Jan. 23	CI
Dicot Files New Manufacturing Technology Patent in Sweden; Stock Rises	Jan. 11	MT
Dicot Applies for Patent Covering New Manufacturing Technology	Jan. 11	CI
Dicot AB Announces Partial Results from Phase 1 Trial to Be Presented Early Next Year	Dec. 15	CI
Dicot AB Initiates Repeat Dosing in its Clinical Study	Nov. 14	CI
Dicot AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	23-10-31	CI
Dicot Sets TO5 Warrant Exercise Price in Rights Issue	23-10-30	MT
Dicot AB Initiates Repeated Dosing in Phase I Study	23-10-24	CI
The Second Part of Dicot's Phase 1 Study Starts on October 20, 2023	23-10-20	CI
Swedish Pharma Company Dicot Files Application under Patent Cooperation Treaty	23-09-26	MT
Dicot AB Applies for International Patent Protection	23-09-26	CI
Dicot AB Announces First Participants Dosed in Phase 1 Trial	23-09-04	CI
Dicot AB Applies for US Patent	23-08-29	CI
Dicot AB Announces Clinical Phase 1 Study Starts	23-08-25	CI
Dicot AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-24	CI
Dicot AB Receives Approval to Start Phase 1 Clinical Trial	23-08-15	CI
Certain Common Shares of Dicot AB are subject to a Lock-Up Agreement Ending on 26-JUL-2023.	23-07-25	CI
Dicot AB Submits Application to Start Clinical Phase 1 Trial	23-06-01	CI
Dicot AB Announces Success in Collaboration with Uppsala University and W. Szafer Institute of Botany	23-05-31	CI
Dicot to Seek Initiation of a Phase I Clinical Trial for the Drug Candidate Lib-01	23-05-23	CI
Dicot AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-19	CI

Chart Dicot AB

Duration

Period

More charts

Company Profile

Dicot AB is a manufacturer of pharmaceutical preparation. The Company is located in Uppsala, Sweden.

Sector

Pharmaceuticals

Calendar

2024-08-21 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
DICOT AB	-18.24%	19.52M
ELI LILLY AND COMPANY	+37.74%	723B
NOVO NORDISK A/S	+32.22%	598B
JOHNSON & JOHNSON	-2.07%	364B
MERCK & CO., INC.	+20.25%	331B
ABBVIE INC.	+2.99%	288B
ASTRAZENECA PLC	+16.60%	244B
NOVARTIS AG	+9.77%	210B
ROCHE HOLDING AG	-5.15%	208B
AMGEN INC.	+7.43%	169B